{"id":50572,"date":"2026-05-26T15:50:16","date_gmt":"2026-05-26T10:20:16","guid":{"rendered":"https:\/\/dailynewsindia.co.in\/index.php\/2026\/05\/26\/fredun-pharmaceuticals-announces-21-bonus-issue-signaling-strong-growth-confidence\/"},"modified":"2026-05-26T15:50:16","modified_gmt":"2026-05-26T10:20:16","slug":"fredun-pharmaceuticals-announces-21-bonus-issue-signaling-strong-growth-confidence","status":"publish","type":"post","link":"https:\/\/dailynewsindia.co.in\/index.php\/2026\/05\/26\/fredun-pharmaceuticals-announces-21-bonus-issue-signaling-strong-growth-confidence\/","title":{"rendered":"Fredun Pharmaceuticals Announces 2:1 Bonus Issue, Signaling Strong Growth Confidence"},"content":{"rendered":"<div>\n<p class=\"wp-block-paragraph\"><strong><strong>Mumbai (Maharashtra) [India], May 26:<\/strong> Fredun Pharmaceuticals Limited (BSE \u2013 FREDUN | 539730),\u00a0<\/strong>one of the leading pharmaceutical formulation manufacturing companies in India, diversified across generics, cosmeceuticals, nutraceuticals, mobility, and animal healthcare products, has announced a\u00a0<strong>2:1 bonus issue of equity shares<\/strong>, underscoring its strong financial performance and continued confidence in future growth.<\/p>\n<p class=\"wp-block-paragraph\">The Board of Directors, at its meeting held on May 25, 2026, wherein the audited financial results for Q4 and FY26 were approved, has recommended the issuance of bonus shares in the ratio of 2:1, i.e. 2 fully paid-up equity shares of\u00a0\u20b910 each for every 1 existing equity share of\u00a0\u20b910 each, to eligible shareholders and warrant holders as on the record date, subject to shareholder approval.<\/p>\n<p class=\"wp-block-paragraph\"><strong>The bonus issue reflects Fredun\u2019s strategic intent to:<\/strong><\/p>\n<ul class=\"wp-block-list\">\n<li>Reward shareholders for their sustained confidence and long-term commitment to the Company\u2019s growth vision\u00a0<\/li>\n<li>Signal management\u2019s confidence in the structural earnings growth and long-term scalability of the business\u00a0<\/li>\n<\/ul>\n<p class=\"wp-block-paragraph\"><strong>With multiple high-growth engines firmly in place<\/strong>\u00a0\u2014 including branded generic exports to 52 countries, domestic Fredun Gx formulations, an integrated pet healthcare platform (Freossi, Wagr and One Pet Stop), nutraceuticals, and cosmeceuticals (Bird N Beauty) \u2014 the Company is well-positioned to sustain its growth trajectory. The inauguration of its 5th GMP-certified manufacturing facility in April 2026 provides significant capacity headroom to support the next phase of scaling across all verticals.<\/p>\n<p class=\"wp-block-paragraph\">This move not only aligns with the company\u2019s consistent value creation philosophy but also reinforces its commitment to delivering\u00a0<strong>long-term, inclusive wealth creation for shareholders<\/strong>.<\/p>\n<p class=\"wp-block-paragraph\"><strong>Commenting on the update,\u00a0Mr. Fredun Medhora, Managing Director, said,\u00a0<\/strong><em>\u201cThe recommendation of a 2:1 bonus issue reflects the strong momentum we have built and our confidence in sustaining this growth trajectory. With robust performance across revenue and profitability, and continued progress in diversifying into higher-value segments such as nutraceuticals, cosmeceuticals, and pet healthcare, we are strengthening the quality and scalability of our business. This bonus is a way of sharing our progress with shareholders while reinforcing our commitment to consistent, long-term value creation.\u201d<\/em><\/p>\n<p class=\"wp-block-paragraph\"><strong>About\u00a0<\/strong><strong>Fredun Pharmaceuticals Limited<\/strong><\/p>\n<p class=\"wp-block-paragraph\">Fredun Pharmaceuticals Limited, a healthcare and pharmaceuticals company, offers a range of products, including antihypertensives, antidiabetics, antiretroviral drugs (ARVs), and narcotics. It is also engaged in the manufacturing of dietary\/herbal supplements, nutraceuticals, cosmeceuticals, and other healthcare products, along with animal healthcare products. With such a diverse range of products, the Company\u2019s objective is to be a holistic healthcare provider. The Company primarily exports its products to Africa, Southeast Asia, Commonwealth of Independent States (CIS) countries, and Latin America.\u00a0<\/p>\n<p class=\"wp-block-paragraph\">In FY26, Fredun reported total revenues of\u00a0\u20b9639.12 Cr, with an EBITDA of\u00a0\u20b994.79 Cr and a PAT of\u00a0\u20b933.21 Cr.<\/p>\n<p class=\"wp-block-paragraph\"><em>If you object to the content of this press release, please notify us at pr.error.rectification@gmail.com. We will respond and rectify the situation within 24 hours.<\/em><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Mumbai (Maharashtra) [India], May 26: Fredun Pharmaceuticals Limited (BSE \u2013 FREDUN | 539730),\u00a0one of the leading pharmaceutical formulation manufacturing companies in India, diversified across generics, cosmeceuticals, nutraceuticals, mobility, and animal healthcare products, has announced a\u00a02:1 bonus issue of equity shares, underscoring its strong financial performance and continued confidence in future growth. The Board of Directors,&#8230;<\/p>\n<p class=\"more-link-wrap\"><a href=\"https:\/\/dailynewsindia.co.in\/index.php\/2026\/05\/26\/fredun-pharmaceuticals-announces-21-bonus-issue-signaling-strong-growth-confidence\/\" class=\"more-link\">Read More<span class=\"screen-reader-text\"> &ldquo;Fredun Pharmaceuticals Announces 2:1 Bonus Issue, Signaling Strong Growth Confidence&rdquo;<\/span> &raquo;<\/a><\/p>\n","protected":false},"author":1,"featured_media":50573,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4],"tags":[54],"class_list":["post-50572","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-business","tag-business"],"_links":{"self":[{"href":"https:\/\/dailynewsindia.co.in\/index.php\/wp-json\/wp\/v2\/posts\/50572","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dailynewsindia.co.in\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dailynewsindia.co.in\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dailynewsindia.co.in\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/dailynewsindia.co.in\/index.php\/wp-json\/wp\/v2\/comments?post=50572"}],"version-history":[{"count":0,"href":"https:\/\/dailynewsindia.co.in\/index.php\/wp-json\/wp\/v2\/posts\/50572\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/dailynewsindia.co.in\/index.php\/wp-json\/wp\/v2\/media\/50573"}],"wp:attachment":[{"href":"https:\/\/dailynewsindia.co.in\/index.php\/wp-json\/wp\/v2\/media?parent=50572"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dailynewsindia.co.in\/index.php\/wp-json\/wp\/v2\/categories?post=50572"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dailynewsindia.co.in\/index.php\/wp-json\/wp\/v2\/tags?post=50572"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}